Latest news with #AMGN
Yahoo
4 days ago
- Business
- Yahoo
Earnings Preview: What to Expect From Amgen's Report
Amgen Inc. (AMGN) is a California-based biopharmaceutical company focused on developing and delivering human therapeutics, especially in oncology, inflammation, bone health, and rare diseases. With a market cap of $159.7 billion, it's known for blockbuster drugs like Prolia, Enbrel, and Repatha. The company is expected to release its fiscal Q2 2025 earnings results after the market closes on Tuesday, Aug. 5. Ahead of this event, analysts expect AMGN to report a profit of $5.21 per share, up 4.8% from $4.97 per share in the prior year's quarter. It has consistently surpassed Wall Street's bottom-line estimates in the past four quarters. More News from Barchart Dear Nvidia Stock Fans, Mark Your Calendars for July 16 Seeking Passive Income? This 'Strong Buy' Dividend Stock Yields 8.6%. How to Buy Tesla for a 13% Discount, or Achieve a 26% Annual Return Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! For fiscal 2025, analysts predict AMGN to post EPS of $20.85, reflecting a 5.1% increase from $19.84 in fiscal 2024. AMGN has declined 11.4% over the past 52 weeks, lagging behind the S&P 500 Index's ($SPX) 10.9% gain and the Health Care Select Sector SPDR Fund's (XLV) 10.3% dip over the same period. On July 1, Amgen shares rose over 4%, outperforming the S&P 500, after announcing positive Phase 3 trial results for its experimental stomach cancer drug, bemarituzumab. The drug, when combined with chemotherapy, significantly improved overall survival in patients with advanced gastric or gastroesophageal cancers compared to a placebo. Analysts' consensus rating on AMGN stock is cautiously optimistic, with a "Moderate Buy" rating overall. Out of 32 analysts covering the stock, opinions include 12 "Strong Buys,' two "Moderate Buy," 15 "Holds,' one "Moderate Sell," and two "Strong Sells.' The average analyst price target for AMGN is $315.15, suggesting a potential upside of 7.7% from current levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-07-2025
- Business
- Yahoo
Piper Sandler Reaffirms Buy on Amgen Amid MariTide Tolerability Update
Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy. On June 24, Piper Sandler reaffirmed its Overweight rating and $328 price target for Amgen Inc. (NASDAQ:AMGN) in response to the company's disclosure of comprehensive MariTide tolerability data. 360b / The obesity medication's gastrointestinal tolerability profile unnerved the market, particularly the frequency of nausea and vomiting, which at first seemed more problematic than alternatives. Piper Sandler's study however, shows that both one- and two-step dose escalation regimens showed a noticeable improvement in the drug's tolerability profile, consistent with management's claims at the December top-line results announcement. According to the firm, the weight loss drug could produce a more commercially acceptable nausea and vomiting profile due to the much lower starting dosages and three-step dose escalation protocols included in the pivotal studies. Amgen Inc. (NASDAQ:AMGN) is a global biopharmaceutical company that focuses on human treatments for cardiovascular, hematology, inflammation, cancer, and bone health. While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
Yahoo
04-07-2025
- Business
- Yahoo
Piper Sandler Reaffirms Buy on Amgen Amid MariTide Tolerability Update
Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy. On June 24, Piper Sandler reaffirmed its Overweight rating and $328 price target for Amgen Inc. (NASDAQ:AMGN) in response to the company's disclosure of comprehensive MariTide tolerability data. 360b / The obesity medication's gastrointestinal tolerability profile unnerved the market, particularly the frequency of nausea and vomiting, which at first seemed more problematic than alternatives. Piper Sandler's study however, shows that both one- and two-step dose escalation regimens showed a noticeable improvement in the drug's tolerability profile, consistent with management's claims at the December top-line results announcement. According to the firm, the weight loss drug could produce a more commercially acceptable nausea and vomiting profile due to the much lower starting dosages and three-step dose escalation protocols included in the pivotal studies. Amgen Inc. (NASDAQ:AMGN) is a global biopharmaceutical company that focuses on human treatments for cardiovascular, hematology, inflammation, cancer, and bone health. While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
28-06-2025
- Business
- Yahoo
Jim Cramer Says That Amgen's Stock 'Did Not Deserve to Get Hit This Hard'
Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street's reaction to the company's latest data announcement regarding MariTide, and said: 'Unlike Mounjaro or Ozempic, which needed to be injected once a week, Amgen's MariTide is one shot per month. I prefer monthly over weekly when it comes to injections any day… So what did we learn when Amgen presented on Monday afternoon? First, the market didn't like it. The stock sold off. Hard response… There… [was] some genuinely new information too. I'm talking about the Phase 1 trial, data from the separate trial, studying much lower starting doses of MariTide with different escalation schedules, far less vomiting at the low doses… A pharmacist filling a prescription for a complex drug developed by the company. Amgen (NASDAQ:AMGN) develops and markets human therapeutics, with a portfolio that includes treatments for conditions such as rheumatoid arthritis, psoriasis, osteoporosis, cancer, cardiovascular disease, and rare disorders. While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
23-06-2025
- Business
- Yahoo
Amgen gears up for phase 3 trial of monthly weight-loss drug MariTide amid mixed investor sentiment
Amgen's (AMGN) late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls patients in its phase 3 trial. The company announced Monday that it has resolved some investors' safety and tolerability concerns about the drug. Rather than jumping from a low to high dose, Amgen will now get patients to the highest dose through a three-step dose escalation, starting at 21 mg and ending at 350 mg doses. Amgen is one of several companies discussing GLP-1s at this week's American Diabetes Conference in Chicago. The company revealed the full data of its phase 2 data, showing 20% weight loss in obese individuals and 17% in those who also have Type 2 diabetes. Investors and physicians alike are closely watching how MariTide performs, as both sides wait to see if it will become a popular option among patients. If the drug is eventually approved by the FDA, it would become the first monthly, or potentially quarterly, injectable weight-loss drug. Read more about Amgen's stock moves and today's market action. Investors have been unimpressed by the 20% weight loss for patients, compared to market leader Eli Lilly's (LLY) Zepbound at up to 24%. In addition, some analysts worried about the safety profile when Amgen first released data, in November 2024, sending the stock down more than 30% that day. Jefferies analysts said in a note to clients Monday that they were "surprisingly bullish" on Amgen's drug because the monthly dosing and ability to tolerate the drug's side effects were "attractive" for patients. "AMGN remains debated by investors, but we still get pretty good feedback from docs on the differentiated profile," the analysts wrote. But Amgen maintains that MariTide's weight-loss potential could be higher, since the patients observed in clinical trials didn't plateau at the end of 52 weeks. The company is following up with longer-term observations and the potential to use MariTide quarterly, rather than monthly. That is key to the doctors' interest in MariTide, the analysts said. Meanwhile, investors feel that Lilly and competitor Novo Nordisk (NVO), with its Wegovy, have a solid hold on the injectable market, and there is little room for new players. Jay Bradner, executive vice president of research and development at Amgen, told Yahoo Finance that he expects the drug to be a competitive offering in the marketplace. "This marketplace is quite large, and is expected to sub-segment as medicines with different properties emerge," Bradner said. "We will never reach ... the segment of the population that loves injecting themselves," he said. "Because a feature of MariTide is this chance for ... much less frequently administered medicine." Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
